Pay in 4 interest-free payments of $22.50 Learn more
Ships within 48 hours · Estimated delivery Aug 1 - Aug 6
PD-161570 suppresses constitutive phosphorylation of the FGF-1 receptor in both human ovarian carcinoma cells (A121(p)) and Sf9 insect cells overexpressing the human FGF-1 receptor and blocked the growth of A121(p) cells in culture
but with much higher IC50 values
Bolaender A
an aurora kinase inhibitor CCT137690
Two hours after LPS stimulation
LX-4211 Size:Solid 2 mg PD-161570 suppresses constitutive phosphorylation ofSotagliflozin, also known as LX4211, is an orally active and a dual SGLT1 SGLT2 inhibitor, which improves glycemic control in patients with type 2 diabetes in a randomized, placebo controlled trial. LX4211 increases serum glucagon like peptide 1 and peptide YY levels by reducing sodium glucose cotransporter 1 (SGLT1) mediated absorption of intestinal glucose. Sotagliflozin is currently being developed by Lexicon for the treatment of type 1 and type 2
US$ 150.00
US$ 178.50